École d’été
SSM11 Summer School in Medicines
SSM11 offers a unique 50-hour training program on drug discovery, development and market access under a multicultural sponsorship in the wonderful setting of Montreal, Quebec. Make plans now for one full week of lively presentations and direct interactions with the Faculty, including Case Studies and Workshops with Industry, covering the whole value chain of medicines, from “idea to market”. SSM11 Faculty members are leaders in their field and contribute to create one of the most innovative and focused programs in drug discovery & development currently offered.
Program
Opening Note
Dear participants to SSM11,
On behalf of the Université de Montréal, it’s a real pleasure for me to welcome you at this 11th edition of the Summer School of medicines. We’re honoured to organize this summer school in collaboration with three of our privileged international academic partners, the University of Barcelona and Université Paul Sabatier in Toulouse and University of Sao Paolo (Brazil).
For several years now, this summer school has represented an important international outreach for us in our mission to train the next generation of scientists in the biopharmaceutical sector. U de Montreal is the 2th largest research U in Canada, with more than 62 thousands students attending, and over 400M Euro in research funding each year. In North America, the region of Montreal is ranked 10th among the major hubs of Biopharmaceutical research. Of the sixinnovative medicines ever developed in Canada and approved by the American FDA, four were developed in the region of Montreal.
Drug discovery is serious business. It has impact on economics, politics, ethics and most importantly on people. Patients who suffer from diseases we don’t yet fully understand. As you will appreciate this week, developing new drugs that are safe and effective is one of the most difficult challenges facing mankind. It involves science, lots of it, in so many different fields that nobody can do it alone in his or her lab. We need specialists that can see the big picture and understand the language of other specialists, their challenges and opportunities, from idea to market.
This is why we are here. To give you the larger picture. Because it is an international school, with faculty and students coming from several countries in the European Union and North America, SSM11 is also an opportunity to make contacts and build your network. Do not hesitate to ask questions either after talks or during the general discussions that will follow at the end each day. Several speakers will stay with us after their talk so see this as an opportunity to meet and discuss with them.
We wish you all the best learning experience possible with SSM11.
Denis deBlois
Chairman, SSM11
For the Scientific and Organizing Committee
SSM11– UNIVERSITE DE MONTREAL – JUNE 8-15, 2019
Program
SATURDAY, June 8, 2019
Pavilion Jean-Coutu, room S1-151 & Agora
15:00 – 16:00 Registration
16:00 – 16:15 OFFICIAL OPENING – 11th Summer School on Medicines (SSM11)
Organizing committee
16:15 – 17:00 Keynote Opening Lecture 1 (KNL1) : New models of translational research from academia to industry
Michel Bouvier, Director of Institute for resesarch in immunology and cancer (IRIC), Montréal
17:00 – 17:45 Keynote Opening Lecture 2 (KNL2): Recent advances in G protein-coupled receptors as therapeutic targets
Jean-Philippe Pin, Director of Functional Genomic Institute (IGF), Montpellier, France
17:45 – 20:00 Poster Session and Welcome Reception at Pavilion Jean-Coutu
SUNDAY, June 9, 2019
Pavilion Jean-Coutu, room S1-151 & Agora
SESSION I : DRUG R&D, AN OVERVIEW FROM TARGET TO MARKET
Chairperson: Jordi Quintana
9:00 – 10:15 (L1) Overview of drug discovery
Denis deBlois UdeM
10:15 – 10:45 Health break
10:45 – 12:00 (L2) Overview of clinical development
Dan Chiche, Chief Medical Officer, Neomed Institute, Montreal
12:00 – 13:00 Lunch
13:00 – 14:00 (L3) Molecules and money: Overview of business development
Steven Klein, VP Business Development, IRIC-Commercialization of Research (IRICoR), Montreal
14:00 – 15:00 (L4) Novel, non obvious, useful? Intellectual property as a discovery engine
Steven Lam, Partner and Patent Agent at ROBIC, S.E.N.C.R.L. / LLP
15:00 – 15:15 Health break
15:15 – 15:45 Plenary discussion with speakers
15:45 – 17:30 Participant Mini-Symposium : Oral and poster presentations
MONDAY, June 10, 2019
Pavilion Jean-Coutu, room S1-151 & Agora
SESSION II : DRUG DISCOVER
Chairperson (AM): Pierre Cordelier
Chairperson (AM): Pierre Cordelier
8:45 – 9:30 (L5) Targeting TNF-alpha to overcome resistance to immunotherapy in melanoma
Bruno Ségui, Centre de recherches en cancérologie de Toulouse
9:30 – 10:15 (L6) Drug discovery – Small molecule
Rodolfo Lavilla, U de Barcelona – Institute of Biomedicine (IBUB)
10:15 – 10:30 Health break
10:30 – 11:15 (L7) Chemical biology
Jordi Quintana, U Pompeu Fabra, Barcelona
11:15 – 12:00 (L8) Beyond the pill: Systems Pharmacology in Drug Discovery
Rafael Najmanovich, UdeM
12:00 – 13:00 Lunch
Chairperson (PM): Marçal Pastor-Anglada
13:00 – 13:45 (L9) Biological drugs : development and manufacturing challenges
Yves Durocher, National Research Council of Canada
13:45 – 14:30 (L10) Oncolytic virus for cancer therapy: from cellular determinants to mathematical modeling of infection
P Cordelier, INSERM, Toulouse
14:30 – 14:45 Health break
14:45 – 15:30 (L11) Beyond the pill: Anti-inflammatory dendrimers call into question pharmaceutical dogmas
Remy Poupot, U Paul Sabatier, Toulouse
15:30 – 16:00 Plenary discussion with speakers
16:00 – 17:00 Visit of IRIC Drug Discovery Platforms (HTS– Medicinal chemistry – Histology– Cytometry )
TUESDAY, JUNE 11, 2019
Pavilion Jean-Coutu, room S1-151
SESSION III : NONCLINICAL DEVELOPMENT
Chairperson: Rémy Poupot
8:45 – 9:30 (L12) Drug-like properties for optimal drug delivery
Grégoire Leclair, UdeM
9:30 – 10:15 (L13) Membrane proteins in drug-transporter interactions
Marçal Pastor-Anglada, U de Barcelona – Institute of Biomedicine (IBUB)
10:15 – 10:30 Health break
10:30 – 11:15 (L14) Toxicology / Non clinical safety evaluation
Violetta Dimitriadou, VP Scientific Operations, IRICoR, Montreal
11:15 – 12:00 (L15) Beyond the Pill – Modeling and simulation to optimize PK / PD relationship
Fahima Nekka, UdeM
12:00 – 13:00 Lunch
- SESSION IV : CASE STUDY – INTELLECTUAL PROPERTY AND TECHNOLOGY WATCH
13:00 – 13:30 Case presentation and outline of challenges
Remy Poupot, U Paul Sabatier, Toulouse
13:30 – 16:00 Group session (students work in small teams) – Health break at convenience 16:00 – 17:00 Each team reports / General discussion
WEDNESDAY, JUNE 12, 2019
Pavilion Jean-Coutu, room S1-111
SESSION VI: CLINICAL DEVELOPMENT & POST-MARKETING FOLLOW-UP
Chairperson: Denis deBlois
8:30 – 9:20 (L16) Learning studies : First-in-Man (Phase I)
Marc Lefebvre, Cofounder of Algorithme Pharma – An Altasciences Company
9:20 – 10:10 (L17) Learning studies : Proof of concept studies (Phase II)
Marc Riviere, General Partner & CMO, TVM Life Science Management Inc
10:10 – 10:40 Health break
10:40 – 11:30 (L18) Confirmatory studies (Phase III) : the perspective of the regulatory agency
Ariel E. Arias, Senior Advisor, Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Canada
11:30 – 12:00 12:00 – 13:15 13:15 – 14:15
Plenary discussion with speakers
Lunch
(L19) Safety in the Real-World : Pharmacovigilance and Therapeutic Risk Management
Yola Moride, UdeM
SESSION VII : CASE STUDY II – REGULATORY STRATEGIES
14:15 – 14:45 Case presentation and outline of challenges
Patrick Colin, PCC Inc
14:45 – 15:00 15:00 – 16:00 16:15 – 17:00
Health break
Group session (students work in small teams) Each team reports / General discussion
THURSDAY, JUNE 13, 2019
Pavilion Jean-Coutu, room S1-111
8:45 – 9:30 (L20) Working with the FDA and other government agencies on clinical trials
Mark Kester, Director, Nanostar Institute, Virginia USA
SESSION VIII : CASE STUDY III – STAKEHOLDERS’ PERSPECTIVES (Part 1)
9:30 – 10:00 Case presentation and outline of challenges
Denis deBlois UdeM
10:00 – 11:00 Group session (students work in small teams) 11:00 – 11:15 Health break
SESSION IX: MARKET ACCESS
11:15 – 12:00 (L21) Pharmaco-economics 101
Alice Dragomir, McGill U
12:00 – 13:00 Lunch
13:00 – 13:45 L(22) Third payer perspective : Health technology assessment
Sylvie Bouchard, Director of drug evaluation, INNESS
13:45 – 14:30 (L23) Market access – Industry perspective
Frédéric Lavoie, VP Access and Government Relations, Pfizer Canada
14:30 – 15:00 15:00 – 15:30 15:30 – 16:15
Plenary discussion with speakers Health break
(L24) Start-up Creation, From the Bench to the Bedside, the journey of a faculty entrepreneur
Mark Kester, Director, Nanostar Institute, Virginia USA
CASE STUDY – STAKEHOLDERS’ PERSPECTIVES (Part 2)
16:15 – 17:15 Each team reports / General discussion
FRIDAY, JUNE 14, 2019
Pavilion Jean-Coutu, room S1-151 & Agora
INDUSTRIAL SYMPOSIUM – DEEP LEARNING IN CURRENT BIOPHARMACEUTICAL DRUG DEVELOPMENT
Chairperson: Jean-Pierre Moreau, Recherche Continuum, Montreal
9:00 Opening Remarks – Jean-Pierre Moreau, Recherche Continuum
9:15 Metatox: Meta Learning for Assessing Toxicity-Related Drug Safety
Therence Bois, InVivoAI, Montréal
Break
10:15 Introduction of SSM11 keynote speaker – Denis deBlois, Chairman SSM11 10:20 Ceramide Nanoliposomes: A Case Study
Mark Kester, Director, Nanostar Institute, Virginia USA
11:20 Prediction of Clinical QTc Changes Based Upon Preclinical Ion Channel Data
William Crumb, Nova Research Labs, New Orleans
11:50-13:30 Lunch break (not offered on site)
13:30 Proof of Concept Comprehensive Ex-vivo Neurological Assay
Lois Miraucourt, CiToxLAB, Laval
14:05 Neomed/CDRD Join Resources for New Pan-canadian Support to Drug Discovery
Youssef Bennani, adMare BioInnovations, Montréal
Break
14:40 Preclinical & Clinical development of Etripamil for Paroxysmal Systolic Ventricular Tachycardia (PSVT)
Philippe Douville, Milestone Pharmaceuticals, Montréal
15:10 Introduction of SSM11 keynote speaker – Denis deBlois, Chairman SSM11
15:15 Preclinical and Clinical Development of Palovarotene for Ultra-rare Bone Diseases
Michael Harvey, VP Drug Development, Clementia Pharma – An Ipsen Company, Montreal
16:05 Networking cocktail
SATURDAY, JUNE 15, 2019
Pavilion Jean-Coutu, room S1-111
9:00 – 10:00 (L25) Beyond the Pill – AI meets drug R&D
Steven Sanche, Los Alamos National Laboratory, USA
SESSION X : START-UP CREATION, INVESTMENT & BUSINESS DEVELOPMENT
Chairperson: Steven Klein, VP Business development, IRICoR
10:00 – 10:15 Health break
10:15 – 11:00 (L26) Translational research – Stem cell expansion strategy for cancer treatment
Anne Marinier, Institute for resesarch in immunology and cancer (IRIC), Montréal
11:00 – 11:45 (L27) Public-Private Partnerships for Drug Discovery and Development
Steven Xanthoudakis, Chief Business Development Officer at Consortium Québécois en développement du médicament (CQDM)
11:45 – 12:00 Plenary discussion 12:00 – 13:00 Lunch
SESSION XI: CARING ABOUT CAREERS: NAVIGATING THE ECOSYSTEM OF BIOPHARMA
13:00 – 13:45 (L28) Career development in the biopharmaceutical sector
Michelle Savoie, Université de Montréal, Québec
13:45 – 14:00 Plenary discussion with SSM11 faculty
14:00 – 14:15 SSM11 Wrap-up, Closing comments and Overture towards SSM12
Site web SSM11 : https://summerschoolonmedicines7.wordpress.com/
Ce contenu a été mis à jour le 8 janvier 2023 à 20:51.